Clinical consensus advises delaying fillers until GLP-1 weight loss stabilizes

Rapid depletion of facial adipose tissue from GLP-1 receptor agonist-mediated weight loss requires a staged, conservative treatment approach to avoid over-volumization. A clinical review published in The Journal of Clinical and Aesthetic Dermatology outlines a structured protocol for managing the specific tissue laxity and deep volume loss caused by these medications. Authors Kanthi Bommareddy, MD, Sabrina Fabi, MD, and Mariana Muniz, MD, note that this rapid weight loss affects multiple facial planes simultaneously, leading to accelerated aging that cannot be addressed with standard, single-stage filler protocols.

The core recommendation is to avoid administering hyaluronic acid fillers or biostimulators at time zero, before the patient reaches their target weight. Treating too early risks distorted facial proportions once further weight loss occurs. Instead, clinicians should target skin quality and laxity in the early stages using microfocused ultrasound with visualization to recruit fibroblasts and initiate extracellular matrix remodeling.

Once the patient's weight has stabilized, providers can transition to deep volume restoration and maintenance. Recommended modalities for this later stage include calcium hydroxyapatite, poly-L-lactic acid, hybrid hyaluronic acid complexes, and multilayer fat grafting using millifat, microfat, and nanofat. For the clinic, this study provides a clear framework to manage patient expectations, allowing you to sequence treatments safely over several months rather than correcting volume deficit prematurely.

Source: The Journal of Clinical and Aesthetic Dermatology, https://jcadonline.com/aesthetic-considerations-for-preventing-and-managing-glp-1-receptor-agonist-related-facial-aging/